Fibrocell Science, Inc. Accesses Patents from Stanford University on Fibroblast Research to Advance Cell Therapy Fibrocell Science, Inc. announced that it has entered into a scientific collaboration with University of California, Los Angeles to research the conversion of dermal fibroblasts into pure functional human cell types that may have greater regenerative capacity. In addition, Fibrocell announces they have accessed key patents from Stanford University to enable the process. [Fibrocell Science, Inc. Press Release] Epizyme Enters Worldwide Strategic Partnership with Eisai for Cancer Therapeutics Targeting EZH2 Epigenetic Enzyme Epizyme, Inc. announced a worldwide partnership with Eisai Co., Ltd., Tokyo, Japan to discover, develop and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers in genetically-defined patients. [Epizyme, Inc. Press Release] Généthon and Wake Forest University School of Medicine (North Carolina) Announce Their Collaboration for a Preclinical Gene Therapy Trial Généthon and Wake Forest University School of Medicine announced that they are to collaborate on the preclinical development of a gene therapy for myotubular myopathy. [Généthon Press Release] Yissum and Hadasit License Regenerative Polymeric Membrane Implants to RegeneCure Yissum Research Development Company Ltd. and Hadasit Medical Research Services & Development Ltd. announced that they have licensed innovative regenerative membrane implant technology to RegeneCure, which will further develop and commercialize the technology for bone tissue engineering for applications in trauma, spine, and reconstructive cranial and facial orthopedics. [BusinessWire] Liquidia Technologies Receives Significant Equity Investment to Bolster Development of Next Generation Vaccines Liquidia Technologies announced the Bill & Melinda Gates Foundation has made a $10 million program-related investment in the company to support the development and commercialization of safer and more effective vaccines and therapeutics. [Liquidia Technologies Press Release] Kite Pharma Raises $15 Million in Initial Round of Financing and Appoints David Bonderman to Board of Directors Kite Pharma, Inc. announced that it has raised $15 million in an initial round of financing through a private placement with a syndicate of venture and qualified investors. [Business Wire] ACT Receives Positive Opinion for Orphan Drug Designation from European Medicines Agency for hESC-Derived RPE Cells for Treatment of Stargardt’s Disease Advanced Cell Technology, Inc. (ACT) announced that the Committee for Orphan Medicinal Products of the European Medicines Agency has announced a positive opinion of ACT’s human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells for designation as an orphan medicinal product for the treatment of Stargardt’s disease. [Advanced Cell Technology Inc. Press Release] Biovest Is Awarded Orphan Drug Status for its Personalized Cancer Vaccine for the Treatment of Mantle Cell Lymphoma in European Union Biovest International, Inc. announced that BiovaxID®, its personalized cancer vaccine, has been designated as an “Orphan Medicinal Product” by the European Medicines Agency for the treatment of mantle cell lymphoma, which is an aggressive form of non-Hodgkin’s lymphoma. [Biovest International Inc. Press Release] Cytori Patents Method of Making Stem and Regenerative Cell-Enriched Fat Grafts Cytori received U.S. Patent No. 7,901,672 from the United States Patent and Trademark Office for a method of enriching a patient’s own fat with their own adipose derived stem and regenerative cells to create a cell-enriched fat graft. [Cytori Therapeutics, Inc. Press Release] co.don AG Is Awarded the U.S.-Patent – Process to Produce Cell Transplants Patented Successfully The refined method by co.don AG for growing three-dimensional autologous cell transplants is now protected on the U.S. market. [co.don AG Press Release] New Aid for AIDS – ICAP Ocean Tomo Announces Auction of a Keystone Patent for Cell Therapy Use of Modified Red Blood Cells for Treating Viral Diseases Developed by inventor Lawrence F. Glaser and represented by ICAP Ocean Tomo, this technology will be auctioned off at ICAP Ocean Tomo’s Spring 2011 Live IP Auction on March 31, 2011 in New York City. [ICAP Ocean Tomo, LLC Press Release] Athersys Announces Initiation of Patient Enrollment for Phase II Clinical Trial in Inflammatory Bowel Disease Athersys, Inc. announced the initiation of patient enrollment, and dosing of the first patient for a Phase II clinical trial evaluating the safety and efficacy of administration of MultiStem®, Athersys’ allogeneic cell therapy product for the treatment of ulcerative colitis. [Athersys, Inc. Press Release] Adaptimmune Announces Launch of U.S. Subsidiary Adaptimmune Limited announced that it has launched a U.S. subsidiary, Adaptimmune LLC, located in Philadelphia, and appointed Dr Gwen Binder-Scholl as Vice President of Operations of the new company. [Adaptimmune Limited Press Release] CIRM Extends Support to Shared Labs, Providing $22 Million to a Program That Leverages Grants and Enables Collaboration The 17 California Institute for Regenerative Medicine (CIRM) Shared Laboratories will continue receiving support to train stem cell scientists and provide research assistance for an additional three years after the state stem cell agency Governing Board voted to extend funding. [California Institute for Regenerative Medicine Press Release] Case Western Reserve Positions Regenerative Medicine Center for Future Growth In a move to streamline and accelerate the research and development of new stem cell and regenerative medicine technologies, the National Center for Regenerative Medicine and the Center for Stem Cell and Regenerative Medicine at Case Western Reserve University have been rolled into a single entity housed within the university’s School of Medicine. [Case Western Reserve University Press Release] Fortis Healthcare Ties Up with TotipotentRX to Set Up Stem Cell Therapy Center Fortis Healthcare Ltd. and TotipotentRX Cell Therapy Pvt. Ltd. announced a collaboration to set up centers of excellence offering cellular therapies and stem cell clinical trials across select Fortis hospitals. [Fortis Healthcare Limited Press Release] Scottish Stem Cell Network Launch New Community Website to Help Grow Life Science Industry The Scottish Stem Cell Network have launched a new member focused website to assist in the networks role of facilitating communication, learning and collaboration amongst the stem cell and regenerative medicine community – one which is anticipated to be worth £40.2 billion worldwide by 2015, tripling its current value. [PR Web] |